FORT WASHINGTON, Pa. — McNeil-PPC announced Wednesday that the acquisition of full ownership of the Johnson & Johnson-Merck Consumer Pharmaceuticals joint venture has been completed.
The joint venture will be renamed McNeil Consumer Pharmaceuticals and will continue to market products under the Pepcid, Mylantq and Mylicon brands.
In addition, Johnson & Johnson, through its McNeil Consumer Healthcare Division (McNeil Canada) has acquired from Merck Canada its partnership interest in the Canadian joint venture. McNeil Canada will continue to market and sell Pepcid, 222 and Fleet Enema in Canada.
Ownership of the manufacturing facility located in Lancaster, Pa., also will transfer to McNeil-PPC.
Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.